Murray Income Trust: a rare star in the income sector
The Murray Income Trust is a reliable and promising pick in a struggling sector.

In the second quarter of 2020 dividends paid by UK companies fell by 57%. Just a quarter of dividend-paying constituents of the FTSE 350 maintained or increased payments. For the year as a whole, dividends paid by FTSE 100 firms are forecast to be 32% lower than last year.
As a result, the UK equity income section of the funds market has become something of a graveyard, with many five-year performances negative. The sector’s fall from grace has been exacerbated by the exaggerated expectations of the past, based on a combination of the hunt for income in a world of falling bond yields and interest rates, and a misunderstanding of the pattern of historic returns.
Misinterpreting history
Many commentators emphasised the importance of reinvested income to long-term returns, from which they jumped to the non sequitur that investing for income was the way to maximise returns. The flaws in this idea are firstly that investors can’t benefit from compounding if the income is not reinvested. Secondly, the benefit of compounding comes from extracting the income of mature, high-yielding investments and reinvesting it not in the same companies, but in immature growth companies.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Nevertheless, the flood of money into high-yielding shares encouraged managements to pay unsustainable dividends, pushed up share prices and created the illusion of success for many years before it ran out of momentum. As the Neil Woodford debacle showed, the tide was going out for income investing long before the pandemic struck.
Many income-fund managers crowded into the same high-yielding stocks, notably Shell, HSBC and Vodafone. But the shrewder ones focused on companies with moderate but growing yields, rather than high but static ones. Notable among these are Charles Luke and Iain Pyle, managers of the £530m Murray Income Trust (LSE: MUT). Full disclosure: MoneyWeek’s editor-in-chief, Merryn Somerset Webb, sits on the board).
Its shares have returned 30% over five years (far ahead of the FTSE All Share’s 8.5%), trade on a 5% discount to net asset value, but still yield 4.7%. Luke emphasises the importance of “high-quality companies with strong competitive positions, robust financial characteristics and experienced management.
Diversification is helped by having up to 20% of the portfolio listed overseas, a broad range of companies and the avoidance of exposure to any one economic scenario”. The top-20 investments include no banks, no oil majors other than Total (no 16), no Vodafone and no retailers.
Betting on long-term growth
More importantly, the portfolio has barely changed since the start of the year. There has been little or no whitewashing by disposing of embarrassing mistakes.
With companies such as Diageo, Aveva, Unilever and RELX in the top ten, long-term growth is well represented. Healthcare comprises 15% of the portfolio (AstraZeneca, GlaxoSmithKline and Roche). Murray has large holdings in BHP and Rio Tinto.
With a solid record and a sensible portfolio, it is not surprising that Murray Income has been chosen by the directors of Perpetual Income & Growth Investment Trust, the troubled trust previously managed by Invesco, as its merger partner. This should result in cost savings for Murray Income and provide new investors with an opportunity to buy at an attractive price.
UK equity income won’t return to its previous level of popularity, but rumours of its death have been exaggerated. The UK faces significant uncertainties, but valuations of quality British equities were low in absolute and relative terms before the crisis and are even cheaper now. Having ridden the down cycle better than most rivals, Murray Income should profit from the upswing.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Max has an Economics degree from the University of Cambridge and is a chartered accountant. He worked at Investec Asset Management for 12 years, managing multi-asset funds investing in internally and externally managed funds, including investment trusts. This included a fund of investment trusts which grew to £120m+. Max has managed ten investment trusts (winning many awards) and sat on the boards of three trusts – two directorships are still active.
After 39 years in financial services, including 30 as a professional fund manager, Max took semi-retirement in 2017. Max has been a MoneyWeek columnist since 2016 writing about investment funds and more generally on markets online, plus occasional opinion pieces. He also writes for the Investment Trust Handbook each year and has contributed to The Daily Telegraph and other publications. See here for details of current investments held by Max.
-
8 of the best houses for sale with annexes
The best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
By Natasha Langan Published
-
Zelenskyy moves to appease Donald Trump – what happens now?
Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
By Emily Hohler Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fades
Food-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
By Dr Matthew Partridge Published
-
Should investors stay bullish and buy UK and US stocks?
Opinion Ignore the Eeyores, says Max King. The outlook for stocks in both Britain and America remains auspicious
By Max King Published